Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

EHA 2019 /
Dose escalation of REGN1979 in patients with relapsed and refractory B-NHL

13th - 16th Jun 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 20.06.19
Views: 1223
Rating:

Prof Max Topp - University of Würzburg, Würzburg, Germany

Prof Max Topp speaks to ecancer at the 2019 European Hematology Association (EHA) Annual Meeting about a dose escalation trial in patients with relapsed and refractory B-cell non-hodgkin lymphoma using REGN1979 - an anti-CD20 x anti-CD3 bispecific antibody.

He explains that the aim of the study was to determine safety, tolerability and occurrence of dose limiting toxicities - reporting that it was well tolerated and that no dose limiting or neurological toxicities were observed. The maximum tolerated dose was not reached.

Looking forward, Prof Topp suggests that next steps will be focused on the responses of subgroups.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.
 

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation